Piretanide: Difference between revisions

	WikiDoc Resources for Piretanide
Articles
Most recent articles on Piretanide Most cited articles on Piretanide Review articles on Piretanide Articles on Piretanide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Piretanide Images of Piretanide Photos of Piretanide Podcasts & MP3s on Piretanide Videos on Piretanide
Evidence Based Medicine
Cochrane Collaboration on Piretanide Bandolier on Piretanide TRIP on Piretanide
Clinical Trials
Ongoing Trials on Piretanide at Clinical Trials.gov Trial results on Piretanide Clinical Trials on Piretanide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Piretanide NICE Guidance on Piretanide NHS PRODIGY Guidance FDA on Piretanide CDC on Piretanide
Books
Books on Piretanide
News
Piretanide in the news Be alerted to news on Piretanide News trends on Piretanide
Commentary
Blogs on Piretanide
Definitions
Definitions of Piretanide
Patient Resources / Community
Patient resources on Piretanide Discussion groups on Piretanide Patient Handouts on Piretanide Directions to Hospitals Treating Piretanide Risk calculators and risk factors for Piretanide
Healthcare Provider Resources
Symptoms of Piretanide Causes & Risk Factors for Piretanide Diagnostic studies for Piretanide Treatment of Piretanide
Continuing Medical Education (CME)
CME Programs on Piretanide
International
Piretanide en Espanol Piretanide en Francais
Business
Piretanide in the Marketplace Patents on Piretanide
Experimental / Informatics
List of terms related to Piretanide

Piretanide
Clinical data
Trade names	Arelix, Eurelix, Tauliz
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C03CA03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 3-(aminosulfonyl)-4-phenoxy-5-pyrrolidin-1-ylbenzoic acid;
CAS Number	55837-27-9;
PubChem CID	4849;
UNII	DQ6KK6GV93;
KEGG	D01634 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H18N2O5S
Molar mass	362.40 g/mol
3D model (JSmol)	Interactive image;
	SMILES C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3;
(verify)

VisualWikitext

Latest revision as of 16:57, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as furosemide and bumetanide found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive^[1] medication in Germany, France, Italy and other countries.

References

↑ Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.

W.Merkel, D.Bormann, D.Mania, R.Muschaweck and M.Hropot, Eur. J. Med. Chem.-Chim.Ther. 11,399 (1976).
W.Merkel, D.Mania and D.Bormann, Liebigs Ann. Chem. 461 (1979).

[AustriaCodex-1] Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.

[1]

@@ Line 49: / Line 49: @@
 ==Overview==
-'''Piretanide''' ([[International Nonproprietary Name|INN]], trade names '''Arelix''', '''Eurelix''', '''Tauliz''') has been synthesized in 1973 at [[Hoechst AG]] (Germany) as a [[loop diuretic]]<ref>{{cite pmid|19821314}}</ref> compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as [[furosemide]] and [[bumetanide]] found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=3-85200-196-X|language=German}}</ref> medication in Germany, France, Italy and other countries.
+'''Piretanide''' ([[International Nonproprietary Name|INN]], trade names '''Arelix''', '''Eurelix''', '''Tauliz''') has been synthesized in 1973 at [[Hoechst AG]] (Germany) as a [[loop diuretic]] compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as [[furosemide]] and [[bumetanide]] found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=3-85200-196-X|language=German}}</ref> medication in Germany, France, Italy and other countries.
 ==References==

Piretanide: Difference between revisions

Latest revision as of 16:57, 20 August 2015

Overview

References

Navigation menu